Rockwell Medical

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.

Rockwell's lead drug candidate in late-stage clinical development is for the treatment of iron deficiency in dialysis patients and is called Soluble Ferric Pyrophosphate (SFP). SFP delivers iron to the bone marrow of dialysis patients in a non-invasive, physiologic manner via dialysate during their regular dialysis treatment. In completed clinical trials to date, SFP has demonstrated that it can safely deliver sufficient iron to the bone marrow. SFP is nearing completion of its Phase 3 clinical studies (CRUISE-1 and CRUISE-2) and is expected to address an estimated $600M U.S. market.

Rockwell is preparing to launch its FDA approved generic drug called Calcitriol to treat secondary hyperparathyroidism in dialysis patients. Calcitriol active vitamin D injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to launch Calcitriol as soon as it receives FDA manufacturing approval, addressing an estimated $350M U.S. market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell's products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell has three manufacturing and distribution facilities located in the U.S. and its operating infrastructure is a ready-made sales and distribution channel that is able to provide seamless integration into the commercial market for its drug products, Calcitriol and SFP upon FDA market approval.

Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis.

Company Growth (employees)
Type
Public
HQ
Wixom, US
Founded
1995
Size (employees)
300 (est)
Rockwell Medical was founded in 1995 and is headquartered in Wixom, US

Key People at Rockwell Medical

Robert L. Chioini

Robert L. Chioini

Founder, Chairman, CEO & President
Thomas E. Klema

Thomas E. Klema

VP & CFO

Rockwell Medical Office Locations

Rockwell Medical has an office in Wixom
Wixom, US (HQ)
30142 Wixom Road

Rockwell Medical Data and Metrics

Rockwell Medical Financial Metrics

Rockwell Medical's revenue was reported to be $14.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

14.6 m

Gross profit (Q1, 2017)

2.4 m

Gross profit margin (Q1, 2017), %

16%

Net income (Q1, 2017)

(4.7 m)

EBIT (Q1, 2017)

(5 m)

Market capitalization (18-Aug-2017)

321 m

Cash (31-Mar-2017)

11.9 m
Rockwell Medical's current market capitalization is $321 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

52.4 m54.2 m55.4 m53.3 m

Revenue growth, %

3%2%(4%)

Cost of goods sold

11.9 m11.9 m12.1 m46.5 m

Gross profit

40.5 m42.3 m43.3 m6.8 m

Gross profit Margin, %

77%78%78%13%

General and administrative expense

21.1 m

Operating expense total

21.1 m

EBIT

(7.5 m)(5 m)(6.1 m)(20.2 m)

EBIT margin, %

(14%)(9%)(11%)(38%)

Interest expense

872.4 k1.5 m(4.2 m)

Pre tax profit

(8.3 m)(6.4 m)(5.8 m)(19.4 m)

Income tax expense

404.5 k

Net Income

(48.8 m)(21.3 m)(14.4 m)(19.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

13 m13.7 m13.9 m13 m14.4 m13.6 m13.5 m12.8 m14.6 m

Cost of goods sold

11 m11.5 m11.6 m10.9 m11.9 m11.9 m12 m11.2 m12.2 m

Gross profit

2 m2.3 m2.3 m2.1 m2.5 m1.7 m1.5 m1.6 m2.4 m

Gross profit Margin, %

15%17%17%16%17%12%11%12%16%

General and administrative expense

4.2 m4.1 m5.3 m3.8 m3.8 m5 m5 m5.1 m6.1 m

Operating expense total

4.2 m4.1 m5.3 m3.8 m3.8 m5 m5 m5.1 m6.1 m

EBIT

(2.4 m)(3.1 m)(3.8 m)(2.7 m)(2.6 m)(4.6 m)(5.6 m)(4.8 m)(5 m)

EBIT margin, %

(18%)(23%)(27%)(20%)(18%)(34%)(42%)(37%)(34%)

Interest expense

858 k892 k854.3 k858 k892 k

Pre tax profit

(3.2 m)(4 m)(3.7 m)(2.5 m)(2.4 m)(4.4 m)(5.4 m)(4.6 m)(4.7 m)

Income tax expense

404.5 k404.5 k(404.5 k)404.5 k

Net Income

(3.2 m)(14.9 m)(3.7 m)(2.5 m)(2.4 m)(4.8 m)(5.4 m)(4.6 m)(4.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

11.9 m65.8 m31.2 m17.2 m

Inventories

2.8 m3.9 m7.9 m12.1 m

Current Assets

31.9 m94.7 m84.6 m78.5 m

PP&E

1.6 m1.5 m1.6 m1.4 m

Goodwill

920.7 k920.7 k920.7 k920.7 k

Total Assets

36.4 m98 m87.8 m83.2 m

Accounts Payable

8.7 m5.3 m4 m5.9 m

Current Liabilities

17.8 m9.8 m8.1 m10.1 m

Retained Earnings

(158.8 m)(180.1 m)(194.5 m)(214.3 m)

Total Equity

595.5 k68.7 m62.3 m53 m

Financial Leverage

61.1 x1.4 x1.4 x1.6 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

2.9 m3 m63.3 m37.1 m33.2 m30 m23.8 m19.3 m11.9 m

Accounts Receivable

2.2 m

Inventories

2.8 m3 m5.2 m6.3 m7.4 m9.2 m11 m11.8 m13.4 m

Current Assets

21.7 m19.9 m94 m88.4 m87.9 m85.8 m84 m79.8 m74.8 m

PP&E

1.7 m1.6 m1.4 m1.4 m1.3 m1.7 m1.6 m1.5 m1.4 m

Goodwill

920.7 k920.7 k920.7 k920.7 k920.7 k920.7 k920.7 k920.7 k920.7 k

Total Assets

25.9 m23.9 m97.2 m91.5 m90.9 m89.1 m87.1 m82.9 m80.5 m

Accounts Payable

6.3 m5.2 m5.1 m4.3 m5.2 m4.4 m5 m3.4 m3.9 m

Current Liabilities

15.3 m17.3 m10.3 m7 m8.5 m8 m9.2 m7.3 m10.4 m

Retained Earnings

(169.8 m)(173.7 m)(183.8 m)(186.4 m)(188.8 m)(199.4 m)(204.7 m)(209.3 m)(219.1 m)

Total Equity

(3.9 m)(5.5 m)67.8 m66 m64.4 m60.2 m57.6 m55.8 m50.6 m

Financial Leverage

-6.6 x-4.4 x1.4 x1.4 x1.4 x1.5 x1.5 x1.5 x1.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(8.3 m)(21.3 m)(5.8 m)(19.8 m)

Depreciation and Amortization

1 m996.3 k822.3 k762.4 k

Accounts Receivable

(146.4 k)106.3 k(574.7 k)(1.2 m)

Inventories

(150 k)

Accounts Payable

(6.1 m)(3.4 m)1.9 m

Purchases of PP&E

(654.2 k)(684.6 k)(815 k)(355.3 k)

Cash From Financing Activities

70.5 m58.5 m2.8 m80.2 k

Interest Paid

1.2 m3.5 m3.5 m

Income Taxes Paid

404.5 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.2 m)(14.9 m)(3.7 m)(2.5 m)(2.4 m)(4.8 m)(5.4 m)(4.6 m)(4.7 m)

Depreciation and Amortization

506.5 k767.4 k207.9 k408.3 k608.2 k200.1 k396 k583.5 k130.2 k

Accounts Receivable

359.4 k388.7 k(193.8 k)533.2 k(1.4 m)(2.5 m)(3 m)(344.5 k)

Inventories

15.5 k(2.4 m)

Accounts Payable

(2.4 m)425.3 k981 k(598.4 k)(1.9 m)

Purchases of PP&E

(428.8 k)(613.3 k)(77.7 k)(208.6 k)(336.9 k)(202.4 k)(229.3 k)(328.3 k)(162 k)

Cash From Financing Activities

2 m2.1 m918.9 k1.6 m1.6 m77.3 k77.3 k80.2 k77.3 k

Interest Paid

1.3 m1.9 m628.2 k1.3 m1.9 m404.5 k
USDY, 2017

Revenue/Employee

48.6 k

Financial Leverage

1.6 x

Rockwell Medical Market Value History

Traffic Overview of Rockwell Medical

Rockwell Medical Online and Social Media Presence

Rockwell Medical Company Life and Culture

You may also be interested in